Introduction
============

Migraine is a chronic-intermittent primary headache disorder that affects roughly 15% of the Western population \[[@b1-jos-2019-00332]\]. Although migraine, in particular migraine with aura, has been shown to be associated to ischemic stroke \[[@b2-jos-2019-00332]\], the exact mechanisms underlying this relation remain unclear.

Potential biologic processes include endothelial dysfunction, hypercoagulability, platelet aggregation, vasospasm, shared cardiovascular risk factors and genetic risk, paradoxical embolism, and use of nonsteroidal anti-inflammatory drugs \[[@b3-jos-2019-00332]-[@b8-jos-2019-00332]\].

Recent experimental evidence in mice has suggested that cerebral hyperexcitability and enhanced susceptibility to spreading depolarization, the electrophysiologic event underlying migraine, may be one additional mechanism involved in the migraine-stroke association \[[@b9-jos-2019-00332],[@b10-jos-2019-00332]\]. The increased cerebral excitability of migraineurs may facilitate infarction if and when the tissue becomes ischemic, by predisposing to frequent ischemic depolarizations. According to this pathogenic hypothesis, it might be that elevated cerebral blood flow threshold for viability, a sign of increased vulnerability to ischemia, may promote rapid infarct expansion into tissue with milder perfusion deficits, diminish salvageable tissue at risk, and result in larger infarcts in susceptible migraineurs. Currently, a paucity of data is available to substantiate this experimental model in clinical setting \[[@b11-jos-2019-00332],[@b12-jos-2019-00332]\], and, in particular, whether patients with personal history of migraine actually develop larger infarct volumes has not been properly investigated so far. To explore this hypothesis, in the present study we, therefore, sought to determine whether acute infarct volume, as well as the volume of chronic cerebral infarcts, assessed by volumetric magnetic resonance imaging (MRI) analysis, are associated with migraine and its subtypes in a large, prospective, hospital-based cohort of young patients with acute ischemic stroke.

Methods
=======

Study design and study population
---------------------------------

The Italian Project on Stroke at Young Age (IPSYS) is a countrywide network of neurological centers with special interest in cerebral ischemia at young age across Italy, aimed at recruiting white patients with first-ever acute stroke who fulfill the following criteria: (1) age 18 to 45 years, (2) computed tomography (CT)- or MRI-proven cerebral infarction, in the setting of a hospital-based, multicentre, observational study \[[@b13-jos-2019-00332]\] ([Appendix 1](#app1-jos-2019-00332){ref-type="app"}). The study was approved by the local Ethics Committee. Written informed consent was obtained for all participants (or next of kin). Centers were included in the IPSYS network provided that the recruitment process of stroke cases takes place prospectively. Stroke was defined as a sudden loss of global or focal cerebral function that persisted for \>24 hours with a probable vascular cause \[[@b14-jos-2019-00332]\]. Ischemic stroke due to sinus venous thrombosis, vasospasm after subarachnoid hemorrhage, cardiac surgery, occurring as an immediate consequence of trauma, and iatrogenic strokes were excluded. The recruitment period for the present study was January 2006 through December 2015.

Clinical and laboratory investigations
--------------------------------------

All patients underwent an etiologic workup including complete blood cell count, biochemical profile, urinalysis, 12-lead electrocardiogram, chest roentgenography, Doppler ultrasonography with frequency spectral analysis and B-mode echotomography of the cervical arteries, transcranial Doppler ultrasonography, and CT and/or magnetic resonance angiography to investigate extracranial and intracranial vessels. Coagulation testing included prothrombin and activated partial thromboplastin times, circulating anti-phospholipid antibodies, fibrinogen, protein C, protein S, activated protein C resistance, antithrombin III, genotyping to detect factor V Leiden and the G20210A mutation in the prothrombin gene. Transthoracic and/or transesophageal echocardiography were performed to rule out cardiac sources of emboli. Based on the results of such investigations, patients were classified according to a classification based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria, accommodated and validated for the cause of stroke in the young \[[@b15-jos-2019-00332]\] and divided into five etiologic categories: (1) atherosclerotic vasculopathy; (2) non-atherosclerotic vasculopathy; (3) small-vessel disease; (4) cardioembolism; and (5) other: cerebral infarction that did not meet the criteria for one of the categories outlined \[[@b16-jos-2019-00332]\].

Potential confounders
---------------------

Hypertension was defined as systolic blood pressure ≥140 mm Hg and diastolic pressure ≥90 mm Hg in two separate measurements after the acute phase or use of antihypertensive drugs before recruitment. Diabetes mellitus as history of diabetes mellitus, use of hypoglycemic agent or insulin, or fasting glucose ≥7.0 mmol/L. Smoking history was defined as "current smoking," including former smokers who had quit smoking for 6 months before the index event, versus "ever smoking" or "never smoking." Hypercholesterolemia as cholesterol serum levels ≥5.7 mmol/L or use of cholesterol-lowering drugs. Current use of oral contraceptives included current user as well as former users who had quit taking these medications for 1 month before the index event. Family history of stroke was defined when stroke was recorded in first-degree relatives by interviewing probands or family members. We also collected information on heavy alcohol consumption (weekly consumption \>14 drinks for men and \>7 drinks for women), personal history of coronary artery disease (history of physician diagnosed angina or myocardial infarction), and atrial fibrillation (medical history or electrocardiographic findings at admission).

MRI protocol
------------

Brain MRI scans were executed on 1.0- and 1.5-tesla scanners. Image analysis was applied to the MRI closest to the onset of clinical symptoms. The MRI protocols included turbo spin echo (TSE) and fluid-attenuated inversion recovery (FLAIR) T2-weighted images and diffusion-weighted images acquired on axial plane and, where available, gradient echo (GE) T2\*-weighted images acquired on axial plane and three-dimensional time-of-flight (3D TOF)-magnetic resonance angiography images. For each image series, 20 slices covering the entire brain (matrix 240 -- 256 × 256 -- 320; field of view 22 to 24 cm; thickness 5 mm; interslice gap 1.5 mm) were obtained. Time repetition/time of echo/time of inversion/flip angle values were optimized on each scanner for the best available image contrast and resulted comparable across the centers.

All MRI available in electronic format were collected, securely stored, and analysed centrally (Brescia University Hospital). An acute brain infarct was defined as a non-mass parenchymal defect, hyperintense on T2, with a vascular distribution, with elevated signal in high b-value diffusion-weighted MRI (DWI) images and low signal in apparent diffusion coefficient (ADC) maps. A chronic brain infarct was identified as non-mass lesion, isointense to cerebral-spinal fluid in all sequences, with low signal in high b-value DWI and an elevated signal in ADC maps.

Image assessment
----------------

Magnetic resonance studies were evaluated by a neuroradiologist (M.B.) and a neurologist trained in neuroimaging (V.D.G.) who were blinded to the diagnosis and clinical data. For each patient, DWI confirmation of acute cerebral infarction was needed.

Volumetric calculation of infarcted areas
-----------------------------------------

Axial T2 fluid-FLAIR images were converted from Digital Imaging and COmmunications in Medicine (DICOM) to analyze format for computer-assisted calculation of the infarct volume, using ANALYZE 11.0 (Mayo Clinic, Rochester, MN, USA). The Intensity Loaded Volume-Region of Interest function was used to optimize intensity settings, thereby enhancing contrast between gray and white matter, infarcted tissue and normal brain and assist in boundary definition. A region-of-interest map of brain infarcts was created by signal intensity thresholding on axial TSE/FLAIR images, followed by manual semiautomatic editing (Region of Interest module) and automatic calculation of the lesion volume. Number, location, and volume of acute, and chronic infarcts were recorded.

Migraine assessment
-------------------

Personal history of headache was assessed in all participants by study physicians during a face-to-face interview with patients and/or family members in both acute phase and followup evaluations. The diagnosis of migraine, as well as its subtypes migraine without aura and migraine with aura was made according to the diagnostic criteria of the Headache Classification Committee of the International Headache Society \[[@b17-jos-2019-00332]\].

Statistical analyses
--------------------

Infarct volumes were log-transformed for all analyses in this study. All variables were reported as either a mean value (±standard deviation), a median value with an interquartile range (IQR) or a proportion/percentage of total. For descriptive analyses, we compared patients characteristics by migraine subgroups (migraine vs. non-migraine; migraine without aura vs. migraine with aura vs. non-migraine) using the chi-square test, Median-test, and Anova *F*-test, as appropriate. Inter-rater reliability in MRI measurements was assessed by having the two examiners categorize the same set of images in a subgroup of 30 patients and was calculated using interclass correlation (ICC) for single measures of acute volumes. The same approach was used to evaluate the reliability of volume calculation on FLAIR images versus DWI images. Using a linear regression model of the log (acute infarct volume) values we assessed the change in log-volumes of acute infarct volume as well as chronic infarct volume in patients with migraine (and its subtypes migraine without aura and migraine with aura) and migraine-free patients. Regression analyses were adjusted for covariates that reached a *P*\<0.05 in univariate analysis. Because of their potential influence on final infarct volume we also planned to include the following variables in the model, regardless of their distribution in the two subgroups of patients defined by migraine status: (1) time from stroke onset to MRI; (2) presumed etiology of brain ischemia (categorized according to the TOAST criteria); (3) large vessel occlusion (occlusion vs. non-occlusion); (4) acute reperfusion therapy (intravenous tissue plasminogen activator and/or mechanical thrombectomy vs. no reperfusion therapy); (5) arterial recanalization (complete recanalization \[defined as a Thrombolysis in Cerebral Infarction score of IIb or higher at the end of the endovascular procedure \[[@b18-jos-2019-00332]\]\] vs. other). To explore potential effect measure modification, we also performed analyses stratified by sex. Results are given as exp (beta)=median ratios (MRs) with 95% confidence intervals (CI). *P*≤0.05 on 2-sided test was considered significant. Data were analyzed using the SPSS version 21.0 software package (IBM Co., Armonk, NY, USA).

Results
=======

Fourteen of the 22 centers included in the IPSYS network participated to the present imaging study. The remaining eight centers were unable to obtain endorsement of the MRI analysis by the local health authority. In all, 600 patients qualified for the study. Nine of these were excluded due to presence of contraindications for MRI scan (e.g., pregnancy, claustrophobia, cardiac electronic devices; n=3), because they died before brain MRI was performed (n=2), or because magnetic resonance images were not suitable for volumetric measurement due to poor quality (n=4). Hence, data from 591 patients (male, 53.8%; mean age, 37.5±6.4 years) were entered into the analysis. Of these, 160 (27.0%) had a personal history of migraine (migraine without aura/migraine with aura, 10^3^/57). Migraineurs were similar to non-migraine patients with regard to demographic characteristics and risk factors, although females were more prevalent in the former subgroup and they also reported to assume oral contraceptives at a higher percentage. Also, the prevalence of heavy alcohol consumers among migraineurs was lower compared with that among non-migraineurs. The etiologic categories "cardiac embolism" and "other or undetermined etiology" were the most represented among patients suffering migraine ([Table 1](#t1-jos-2019-00332){ref-type="table"}).

Interobserver agreement was good for acute infarct volumes (ICC coefficient, 0.89; 95% CI, 0.78 to 0.95). Similarly, there was a good agreement for volume measurements on FLAIR images and DWI images (ICC coefficient, 0.83; 95% CI, 0.65 to 0.92). In univariate analysis, patients with personal history of migraine had larger acute infarct lesions than patients with no history of migraine (median, exp \[8.69\]/10^3^=5.9 cm^3^ \[IQR, 1.4 to 15.5\] vs. exp \[7.87\]/10^3^=2.6 cm^3^ \[IQR, 0.8 to 10.1\]; *P*\<0.001). In particular, the largest volumes were observed in the subgroup of patients with migraine with aura (median, exp \[9.11\]/10^3^=9.0 cm^3^ \[IQR, 3.4 to 16.6\] vs. exp \[8.2\]/10^3^=3.6 cm^3^ \[IQR, 1.0 to 14.4\] in patients with migraine without aura; *P*\<0.001) ([Figure 1](#f1-jos-2019-00332){ref-type="fig"}).

These results were apparently not influenced by specific migraine characteristics (i.e., migraine activity and pain severity), though this comparison was possible only in a small subgroup of patients ([Supplementary Table 1](#SD1-jos-2019-00332){ref-type="supplementary-material"}). In the linear regression model of log(acute infarct volume) values including age, alcohol consumption, as well as all the variables with a potential influence on final infarct volume as covariates, a personal history of migraine was an independent predictor of increased acute infarct volumes (*P*\<0.001). Lesion size, in particular, turned out to be more than once and a half as large in this group compared to the group of patients with no history of migraine (MR, 1.80; 95% CI, 1.33 to 2.45). Similarly, the subtype migraine with aura was independently associated with increased acute infarct size in the model including migraine subtypes, lesion volumes being more than 3 and a half times larger in this group in comparison with the reference group of patients with no migraine (MR, 3.62; 95% CI, 2.28 to 5.74). These findings were consistent across sexes ([Table 2](#t2-jos-2019-00332){ref-type="table"}).

As further support to these findings, we observed an increase of the proportion of patients with any migraine as well as with migraine with aura, and a decrease of the proportion of those with no history of migraine, with increasing quartiles of log (acute infarct volumes) (*P* for trend \<0.001) ([Figure 2](#f2-jos-2019-00332){ref-type="fig"}).

Chronic brain infarcts were present in 75 cases (12.7%). The volumes of these silent lesions did not differ significantly between patients with migraine (median, exp \[7.31\]/10^3^=1.5 cm^3^ \[IQR, 0.4 to 4.7\]) and patients who did not suffer migraine (median, exp \[6.91\]/10^3^=1.0 cm^3^ \[IQR, 0.3 to 3.0\]), as well as across migraine subtypes (median, exp \[7.74\]/10^3^=2.3 cm^3^ \[IQR, 1.4 to 14.9\] in patients with migraine with aura vs. exp \[6.81\]/10^3^=0.9 cm^3^ \[IQR, 0.04 to 5.0\] in patients with migraine without aura).

Discussion
==========

In a large series of young patients with ischemic stroke, we have shown that people suffering migraine, especially the subtype migraine with aura, are at risk of developing larger acute brain infarcts, though the burden of silent ischemic lesions does not differ in migraineurs compared with non-migraineurs, nor across migraine subtypes. The data presented here provide evidence that reinforces the experimental observation of a more rapid expansion of the acute ischemic core and, eventually, the development of larger infarcts in transgenic mouse models expressing familial hemiplegic migraine type 1 (FHM1) mutations \[[@b9-jos-2019-00332]\], and extend the results of previous preliminary works, including ours \[[@b11-jos-2019-00332],[@b12-jos-2019-00332]\], linking individual migraine status with increase vulnerability to ischemic brain injury in humans.

The association between migraine and stroke has been subject of considerable debate. Between 2005 and 2018, four meta-analyses included studies involving any stroke and ischemic stroke as outcomes \[[@b2-jos-2019-00332],[@b19-jos-2019-00332]-[@b21-jos-2019-00332]\]. In two of them, the overall risk of stroke was higher in migraineurs \[[@b2-jos-2019-00332],[@b19-jos-2019-00332]\]. Additionally, three consecutive meta-analyses showed that migraine with aura is consistently associated with a more than 2-fold increased risk of ischemic stroke \[[@b2-jos-2019-00332],[@b20-jos-2019-00332],[@b21-jos-2019-00332]\]. Such a risk was also around 3-fold higher among women younger than 45 years \[[@b2-jos-2019-00332],[@b20-jos-2019-00332]\], 9-fold higher among current smokers \[[@b2-jos-2019-00332]\], and 7-fold higher among women taking oral contraceptives \[[@b2-jos-2019-00332],[@b20-jos-2019-00332]\]. More recently, data from Atherosclerosis Risk in Communities (ARIC) study suggested increased incidence of atrial fibrillation and cardioembolic stroke in older migraineurs with visual aura \[[@b22-jos-2019-00332]\], especially among subjects with late onset migraine with aura \[[@b23-jos-2019-00332]\]. Taken together, despite some conflicting evidence \[[@b24-jos-2019-00332]-[@b26-jos-2019-00332]\], these findings and our own results support the prevailing idea that migraine is a highly prevalent and perhaps modifiable predisposing factor for brain ischemia, though the exact mechanisms underlying this relationship remain to be clarified. Several biologic pathways implicated in cerebral blood vessel dysfunction have been advocated, including hypercoagulable states, inflammation, platelet and white blood cell endothelial interactions, among the others \[[@b27-jos-2019-00332]\]. It might be possible that these mechanisms play also a role in the relation between migraine and infarct growth in combination with an underlying condition of increased susceptibility to brain ischemia of migraineurs, thus lending indirect support to the hypothesis of a common pathophysiology for the two diseases, at least in a subset of patients.

Whether migraine may result in increased acute infarct volume outside of the experimental settings has not been properly investigated so far. Actually, only two previous analyses have attempted to provide information on the association between migraine and lesion volume from acute cerebral ischemia in humans. The first is a retrospective analysis of the Norwegian Stroke Research (NORSTROKE) registry \[[@b28-jos-2019-00332]\], which suggested that, as opposed to what observed in our study, migraine may be associated with smaller volume of acute infarcts. The second is a single-center North American study conducted on a relatively small group of acute ischemic stroke patients showing, as suggested from the present analysis, an increased lesion volume among migraineurs with aura \[[@b29-jos-2019-00332]\]. The reason for these conflicting results may be due, at least to some extent, to methodological issues. As admitted by the authors themselves, the results of the first analysis might be biased by the lack of a rigorous imaging-based volumetric measurement of the brain lesions as well as by the huge number of patients excluded because of more severe stroke symptoms, likely reflecting large infarct size. Also, because of their demographic characteristics, participants to the NORSTROKE registry are probably not the ideal population to investigate. Similarly, the lack of relevant information on clinical and imaging features of the study group, an unavoidable consequence of its characteristics of preliminary report, represents the major shortcoming of the second study and limits the interpretation and generalizability of its findings. Contrary to these previous reports, our study was carried out to test the specific a priori hypothesis on a large number of well-characterized young patients with acute ischemic stroke, migraine status was assessed through direct interview with physicians according to internationally acknowledged criteria, and the same MRI protocol for infarct volume measurement was applied to all study participants. Further strengths of our study include its prospective nature, the central analysis of brain images, and the high interobserver agreement on the measurement of lesion volume.

On the other hand, there are some potential limitations of our analysis worthy of consideration. First, since we did not assess migraine frequency and severity or the frequency of auras, we cannot evaluate whether the observed association differs according to specific migraine patterns. However, whether the clinical features of migraine have any influence on the individual risk of stroke has never been demonstrated. Also, we did not have information on migraine-specific prophylactic drug use, such as, for example, the use of topiramate or lamotrigine, which has been suggested in previous experimental models to protect migraineurs against ischemic injury \[[@b30-jos-2019-00332]\]. Second, we assessed migraine history by self-report, which raises the possibility of recall bias, creating the potential for misclassification of exposure. This is, however, an unavoidable feature of any epidemiologic study on the relation between migraine and stroke. Third, we cannot exclude that infarct size might depend on other, undetected or hitherto unknown, factors of which migraine is only a marker or an epiphenomenon. Even in this case, however, the hypothesis of a relation between migraine and infarct volume would still be valid and support the external validity of our results. Finally, since participants in this study were aged 18 to 45 years and white, generalizability to other populations might be limited.

Conclusions
===========

With this caveat in mind, we conclude that the present results support the experimental observations in mice and the sparse data in humans that a personal history of migraine is associated to larger acute infarct volumes, probably through a condition of migraine-associated cerebral hyperexcitability, point toward the possibility that this may be one of the biologic mechanisms underlying the migraine-stroke association, and indirectly strengthen the testable hypothesis that treatment aimed at inhibiting cerebral spreading depolarization might protect migraineurs at risk of stroke.
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###### 

Relation between infarct volumes, migraine activity, and pain severity
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###### 

Demographic and clinical characteristics of study participants by migraine status

  Characteristic                                                         Migraine (n=160)    Non-migraine (n=431)   *P*
  ---------------------------------------------------------------------- ------------------- ---------------------- ---------
  Age (yr)                                                               36.7±6.2            37.1±6.5               0.443
  Male sex                                                               69 (43.1)           249 (57.8)             0.002
  Hypertension                                                           28 (17.5)           97 (22.5)              0.185
  Diabetes                                                               5 (3.1)             19 (4.4)               0.482
  Hypercholesterolemia                                                   50 (31.3)           107 (24.8)             0.116
  Current smoking                                                        54 (33.8)           174 (40.8)             0.142
  Oral contraceptives^[\*](#tfn1-jos-2019-00332){ref-type="table-fn"}^   42 (46.2)           60 (33.0)              0.046
  Family history of stroke                                               34 (21.3)           86 (20.0)              0.728
  Atrial fibrillation                                                    2 (1.3)             2 (0.5)                0.297
  Cardiac interatrial right-to-left shunt                                90 (56.3)           116 (26.9)             \<0.001
  Heavy alcohol consumption                                              15 (9.4)            73 (16.9)              0.022
  Cause of stroke                                                                                                   0.369
   Large-vessel disease                                                  13 (8.1)            45 (10.4)              
   Non-atherosclerotic vasculopathies                                    32 (20.0)           60 (13.9)              
   Small-vessel disease                                                  14 (8.8)            49 (11.4)              
   Cardiac embolism                                                      50 (31.3)           132 (30.6)             
   Other or undetermined etiology                                        51 (31.9)           145 (33.6)             
  Large artery occlusion                                                 12 (7.5)            35 (8.1)               0.866
  IV thrombolysis/endovascular treatment                                 17 (10.6)           34 (7.9)               0.323
  Vessel recanalization                                                  8 (5.0)             27 (6.3)               0.696
  Time from stroke onset to MRI (hr)                                     32.5 (24.0--45.5)   36.0 (24.0--48.0)      0.167

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

IV, intravenous; MRI, magnetic resonance imaging.

In females.

###### 

MRs estimates of log (acute infarct volumes) values by linear regression

  Characteristic                           MR                  Adjusted MR                                                                        
  ---------------------------------------- ------------------- ------------- -------------------------------------------------------------------- ------------
  Entire cohort                                                                                                                                   
   Any migraine vs. no migraine            1.74 (1.30--2.35)   2.7×10^-4^    1.80 (1.33--2.45)^[\*](#tfn2-jos-2019-00332){ref-type="table-fn"}^   ≤0.001
   Migraine without aura vs. no migraine   1.28 (0.90--1.82)   0.162         1.29 (0.91--1.82)^[\*](#tfn2-jos-2019-00332){ref-type="table-fn"}^   0.157
   Migraine with aura vs. no migraine      3.04 (1.94--4.76)   1.7×10^-6^    3.62 (2.28--5.74)^[\*](#tfn2-jos-2019-00332){ref-type="table-fn"}^   7.3×10^-8^
  Male                                                                                                                                            
   Any migraine vs. no migraine            1.77 (1.16--2.72)   0.009         1.95 (1.24--3.06)^[\*](#tfn2-jos-2019-00332){ref-type="table-fn"}^   0.003
   Migraine without aura vs. no migraine   1.41 (0.84--2.35)   0.193         1.40 (0.83--2.35)^[\*](#tfn2-jos-2019-00332){ref-type="table-fn"}^   0.205
   Migraine with aura vs. no migraine      2.66 (1.38--5.14)   0.003         3.76 (1.89--7.49)^[\*](#tfn2-jos-2019-00332){ref-type="table-fn"}^   ≤0.001
  Female                                                                                                                                          
   Any migraine vs. no migraine            1.59 (1.04--2.42)   0.033         1.64 (1.07--2.52)^[†](#tfn3-jos-2019-00332){ref-type="table-fn"}^    0.024
   Migraine without aura vs. no migraine   1.10 (0.68--1.79)   0.696         1.14 (0.70--1.84)^[†](#tfn3-jos-2019-00332){ref-type="table-fn"}^    0.598
   Migraine with aura vs. no migraine      3.11 (1.67--5.78)   4.2×10^-4^    3.52 (1.87--6.62)^[†](#tfn3-jos-2019-00332){ref-type="table-fn"}^    ≤0.001

MR, median ratio; CI, confidence interval.

Adjusted by age, alcohol consumption, time from stroke onset to magnetic resonance imaging, presumed etiology of brain ischemia (categorized according to the Trial of Org 10172 in Acute Stroke Treatment \[TOAST\] criteria), patent foramen ovale, large vessel occlusion (occlusion vs. non-occlusion), acute reperfusion therapy (intravenous tissue plasminogen activator and/or mechanical thrombectomy vs. no reperfusion therapy), and arterial recanalization (complete recanalization \[Thrombolysis in Cerebral Infarction score of IIb or higher at the end of the endovascular procedure \[[@b18-jos-2019-00332]\]\] vs. other);

Adjusted as in males (\*) and oral contraceptive use.

[^1]: These authors contributed equally to the manuscript as first author.
